Türk Medline
Dokran

POST-COVID-19 VACCINATION TRIMESTER EVALUATION IN MASTOCYTOSIS: A SINGLE-CENTER REAL-LIFE EXPERIENCE

İLKİM DENİZ TOPRAK, SEMRA DEMIR, NİDA OZTOP, AYŞE FEYZA ASLAN, DERYA UNAL, ASLI GELINCIK

Asthma Allergy Immunology - 2023;21(3):226-236

Department of Internal Medicine, Immunology and Allergic Diseases Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

 

Objective: The aim of this study was to evaluate the long-term impact of Coronavirus Disease 2019 (COVID-19) vaccination on mastocytosis. Materials and Methods: Patients with mastocytosis were divided into two groups as those who received COVID-19 vaccination (Group 1) and those who did not (Group 2). In group 1, the history of symptoms related to mast cell activation was obtained for the three-month periods before and after vaccination. Psychological status of both groups was assessed using the Depression, Anxiety, and Stress Scale (DASS-21). A modified Fear of COVID-19 Scale was employed to evaluate the fear of COVID-19 vaccination. Results: Fifty-three patients were included in the study, with six patients not receiving vaccination. The Fear of COVID-19 vaccination score was higher in group 2 (p=0.031). Among the vaccinated patients, 70.2% experienced non-allergic adverse reactions. Only one patient experienced anaphylaxis within 20 minutes after the first dose. None of the vaccinated patients reported any change in the frequency of anaphylaxis episodes after vaccination. Conclusion: To conclude, this study suggested that the COVID-19 vaccine can be safe for patients with mastocytosis in both early and late stages. While, further detailed studies on long-term outcomes are necessary, it is recommended to administer the COVID-19 vaccine to patients with mastocytosis while taking the necessary precautions in accordance with the provided recommendations.